Valopicitabine (dihydrochloride)

Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107) . NM107competitively inhibits NS5B polymerase, causing chain termination[1][2].

Product Specifications

CAS Number

[640725-71-9]

Product Name Alternative

NM283 (dihydrochloride)

UNSPSC

12352005

Target

HCV; HCV Protease; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/valopicitabine-dihydrochloride.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

N[C@H](C(O[C@@H]1[C@H](O[C@H]([C@]1(C)O)N2C=CC(N)=NC2=O)CO)=O)C(C)C.[H]Cl.[H]Cl

Molecular Formula

C15H26Cl2N4O6

Molecular Weight

429.30

References & Citations

[1]Liu-Young G, et al. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 2008;22 (6) :449-457.|[2]Pierra C, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem. 2006;49 (22) :6614-6620.